Uterine fibroids: an update on current and emerging medical treatment options

Manuela Farris1,2
Carlo Bastianelli1
Elena Rosato1
Ivo Brosens3
Giuseppe Benagiano1

1Department of Gynecology, Obstetrics and Urology, Sapienza, University of Rome, Rome, Italy; 2The Italian Association for Demographic Education, Rome, Italy; 3Faculty of Medicine, KU Leuven, Leuven, Belgium

Abstract: Uterine fibroids are the most common gynecological disorder, classically requiring surgery when symptomatic. Although attempts at finding a nonsurgical cure date back to centuries, it is only around the middle of the last century that serious attempts at a medical treatment were carried out. Initially, both progestins and estrogen–progestin combinations have been utilized, although proof of their usefulness is lacking. A major step forward was achieved when peptide analogs of the GnRH were introduced, first those with superagonist properties and subsequently those acting as antagonists. Initially, the latter produced side effects preventing their routine utilization; eventually, this problem was overcome following the synthesis of cetrorelix. Because both types of analogs produce hypoestrogenism, their use is limited to a maximum of 6 months and, for this reason, today they are utilized as an adjuvant treatment before surgery with overall good results. Over the last decade, new, nonpeptidic, orally active GnRH-receptor blockers have also been synthesized. One of them, Elagolix, is in the early stages of testing in women with fibroids. Another fundamental development has been the utilization of the so-called selective progesterone receptor modulators, sometimes referred to as “anti-progestins”. The first such compound to be applied to the long-term treatment of fibroids was Mifepristone; today, this compound is mostly used outside of Western Countries, where the substance of choice is Ulipristal acetate. Large clinical trials have proven the effectiveness of Ulipristal in the long-term medical therapy of fibroids, although some caution must be exercised because of the rare occurrence of liver complications. All selective progesterone receptor modulators produce unique endometrial changes that are today considered benign, reversible, and without negative consequences. In conclusion, long-term medical treatment of fibroids seems possible today, especially in premenopausal women.

Keywords: uterine myomas, progestin, gonadotropin-releasing hormone receptor blockers, selective progesterone receptor modulators, antiestrogens

Introduction

Uterine leiomyomata (myomas, fibroids) are the most common gynecological disorder; as such, it should not be surprising that, over the centuries, a whole series of sometimes very strange approaches have been attempted and unlikely methods proposed, mostly unsupported by any scientific evidence.1,2

Ever since the first hysterectomy was performed, treatment of symptomatic fibroids has been surgical. Different techniques have been employed, initially consisting of total abdominal hysterectomy or myomectomy. To decrease the impact of surgery, several mini-laparotomic techniques, including combined mini-laparotomy-assisted vaginal surgery, have also been utilized.

Major progress has been made with the introduction of laparoscopic techniques, as proven by randomized trials comparing the various approaches.3,4
Laparoscopy, however, posed the problem of removal of large fibroids from the abdominal cavity. To solve it, Steiner et al \(^5\) introduced in 1993 an electrical cutting device later coined “morcellator”. This technique has many advantages and has been widely utilized. Unfortunately, following reports of involuntary dissemination of portions of uterine sarcomas during morcellation, \(^6,7\) the US Food and Drug Administration (US-FDA) issued a warning against its use. To obviate the problem, it has been proposed to carry out morcellation of the uterus or myomas within an insufflated isolation bag. \(^8\) The decision by the FDA stimulated research on the true incidence and therefore on the risks associated with morcellation. A just published nationwide multicenter study in China involving 33,723 subjects calculated the prevalence of malignancy after morcellation: 62 cases (0.18%) were confirmed pathologically as malignant. \(^9\) At present, the situation can be summarized as follows: a small, but not irrelevant, risk of disseminating an occult sarcoma exists during tissue extraction. \(^10\) Containment systems are now available for both power and manual morcellation; tissue fragmentation, therefore, can take place within an enclosed specimen bag. \(^11\)

In 1995, a French group introduced a novel procedure to treat myomas: uterine arteries embolization (UAE) with Ivalon particles. Symptoms resolved in 11 out of 16 patients and in 10, menstrual cycles returned to normal. \(^12\) In 1999, the results of a large trial including 305 patients was published, showing control of menorrhagia in 86% of the cases at 3 months and 92% at 12 months. \(^13\)

Results with this procedure have been reviewed over the last years, concluding that there is strong evidence for both safety and effectiveness of the procedure, with symptom improvement and change in quality of life (QoL). A recent evaluation concluded that outcomes with UAE are similar to those obtained following myomectomy, with an intervention rate at 5 years of 20%–30%. It also concluded that in women wishing to become pregnant, myomectomy may be preferred when no previous surgery has been performed. \(^14\)

A noninvasive technique, magnetic resonance imaging (MRI)-guided Focused Ultrasound Surgery has been available for some times and has been approved by the Medicine (MRI)-guided Focused Ultrasound Surgery has been available for some times and has been approved by the Medicine Administration (US-FDA) in 2004. It consists of a noninvasive thermoablative agent, opening-up promising avenues for the development of medical therapies and have proposed new overall guidelines for the management of fibroids, based on symptoms (bleeding, infertility) and the patient’s age. Irrespective of purely medical considerations, it is a fact that many women would prefer medical treatment over a surgery and, over more than half a century, serious attempts at a medical management of fibroids have been made with a varying degree of success. \(^2\)

The present review aims at evaluating different options for medical treatment, including those combining medical and surgical approaches.

### Medical treatment

Today, it is widely accepted that in subjects with asymptomatic uterine myomas who do not desire pregnancy, no special treatment is required and these patients need only periodic monitoring of their condition. \(^2\) For this reason, the most conservative options that minimize morbidity/risk and optimize outcomes should be selected. \(^19\)

Evidence on medical treatments has been systematically analyzed in 2016 \(^20\) in a total of 75 randomized controlled trials (RCT), concluding that their overall quality was very low and that there was insufficient evidence to recommend any medical treatment in the management of fibroids. Interestingly, the same year another systematic review, \(^21\) after evaluating 52 studies, reached a different conclusion, namely that published information proves the efficacy of a number of agents, opening-up promising avenues for the development of medical alternatives to surgery.

### Progestogens

The first attempts to treat with natural progesterone (P) women with uterine myomas were published in the 1940s; \(^22,23\) then, in 1966, Goldzieher et al \(^24\) utilized for the first time up to 60°C or higher, inducing protein denaturation and resulting in coagulative necrosis, while the skin and overlying tissue layers outside the ablated area remain unaffected. \(^6,15\)

In selected cases, the procedure offers the advantage of preserving fertility.

The technique can be used in a number of diseases, including liver tumor, hepatocellular carcinoma, pancreatic cancer, renal cell carcinoma, prostate cancer, breast cancer, fibroids, bone tumors, atrial fibrillation, glaucoma, Parkinson’s disease, essential tremor, and neuropathic pain. It seems that tissue destruction occurs due to direct heating within the lesion and to the mechanical effects of acoustic cavitation. \(^16,17\)

To help both physicians and patients in choosing the best-suited treatment, Donnez et al \(^14\) have recently attempted an overall analysis of the advantages of both medical and surgical therapies and have proposed new overall guidelines for the management of fibroids, based on symptoms (bleeding, infertility) and the patient’s age.
a synthetic progestin, megestrol acetate, with the aim of obtaining the so-called red degeneration observed occasionally in pregnancy. Within a few weeks, they observed the same histological modifications usually found toward the end of a pregnancy and claimed success. Unfortunately, their work has not been validated.

Today, guidelines usually specify that there is insufficient evidence of benefits from use of progestins and therefore they cannot be advocated as a medical therapy for uterine myomas.25,26

Recently, however, attention has been drawn again on the process of red degeneration: Nakai et al27 claimed that MRI can single out myomas undergoing this degenerative regression, including coagulative necrosis. Red degeneration has also been observed following GnRH analog (GnRHA) treatment.28

The situation is complex because it seems that P exerts a dual action on myomas: it stimulates their growth through upregulating expression of EGF and B-cell lymphoma 2 (Bcl-2) and it inhibits growth through downregulation of insulin-like growth factors (IGF) expression in the cells.29

### Estrogen–progestin combinations (oral contraceptives)

Two different, but equally important issues must be considered when discussing the action of oral contraceptives (OC) on uterine myomas: on the one hand, whether OC use can act to prevent the appearance of fibroids; on the other, whether their use can decrease the size of already existing ones.

As per the first question, in spite of several large investigations, it remains basically unanswered: one trial30 found that prolonged use of OC decreased the risk of harboring fibroids; two other case–control investigations31,32 showed no effect.

The same uncertainty exists for the possibility that OC may have a beneficial effect on the size of already existing fibroids. In 1995, it was reported that the prolonged use of an OC produced a significant shrinkage in myomas’ size;33 however, immediately after, the journal published a formal retraction.34

Thus, at present, it is safe to state that whereas OC use does not carry any increased risk of developing a myoma, no valid data have been presented to support the concept that they can inhibit the growth or decrease the volume of existing fibroids.

### Gonadotropin-releasing hormone receptor blockers

To block the action of the GnRH, two different routes have been followed. The first involved the synthesis of GnRHA with a superagonistic (GnRHSA) or antagonistic (GnRHAT) action. The second involved the synthesis of nonpeptidic substances with the ability of directly blocking the GnRH receptor (GnRHR).

#### GnRH analogs

Nowadays, two types of analogs are utilized: superagonists act through a prolonged activation of the GnRHR, leading to desensitization and consequently to suppressed gonadotropin secretion; the antagonists instead compete with GnRH for receptors on cell membranes, inhibiting the GnRH-induced signal transduction and consequently gonadotropin secretion.35

#### Superagonist analogs

A new era in the conservative treatment of fibroids was inaugurated by Filicori et al36 in 1983 with the publication of the case of a woman with a uterine fibroid where metrorrhagia was quickly stopped and the myoma size significantly reduced following “pituitary desensitization by a luteinizing hormone-releasing hormone analog (GnRHA)”. This report was followed by a large number of trials and gave rise to great hope that a medical treatment of uterine myomas had been finally found and that medical therapy would avoid surgery altogether, at least in older women. Unfortunately, the specific features of this approach, as shown in Figure 1, indicate that, whereas GnRHSA do
shrink most fibroids considerably, myoma’s regrowth and recurrence of symptoms invariably follows discontinuation of treatment. Not only the effect seems to vanish after discontinuing therapy, the use of the analog cannot be prolonged beyond 6 months, because of the untoward consequences of the hypoestrogenism caused by the GnRHA, first and foremost an increased risk of osteoporosis that cannot be counteracted by calcitomin.

In terms of mechanism of action, beside the inhibition of estrogen synthesis, this treatment seems to cause DNA damage in myomas’ cells. Thus, it is recognized that GnRHSA can be useful in two main situations: as a pretreatment before surgery and in combination with the so-called add-back therapy.

**Pretreatment before surgery**

The usefulness of a short (3-month) pretreatment with a GnRHSA has been extensively investigated in a variety of situations.

**Adjuvant in classic surgery**

Several factors may determine the success of pretreatment: first, a classic study by Stovall et al showed that volume shrinkage significantly increases the likelihood to proceed with a vaginal hysterectomy (81% vs 13%; P < 0.05) entailing a shorter hospitalization and convalescence. Unfortunately, these advantages seem to disappear if the size of the uterus exceeds that of an 18-weeks gestation. Another study indicated that in laparotomic surgery, recurring to transverse rather than midline incision may be more feasible. Pretreatment may also be beneficial in specific instances, such as the presence of a large broad ligament or cervical fibroid.

Pretreatment in patients with severe anemia offers three main advantages: stopping abnormal bleeding, improving hematological parameters, and reducing intraoperative blood loss. An interesting observation was made in a three-prong multicenter trial in women suffering from myoma-induced chronic menorrhagia: whereas pretreatment with the association of a GnRHS and iron supplementation did stop the bleeding altogether and restored satisfactory hemoglobin (Hb) red cell concentration, paradoxically, the group with iron-only supplementation fared better than the one receiving only GnRHSA (Figure 2). This might have been due to the chronic nature of excessive bleeding in these women.

A systematic review published in 2002 indicated that pretreatment with a GnRHSA produces an increase in Hb and hematocrit, although its clinical relevance may be questionable. Two, although arbitrary, cutoff points have been described to identify patients who will benefit from pretreatment: Hb concentration <12.0 g/dL and red cell concentration <3×10^12/L. Much will depend on whether menorrhagia had continued for a long period of time, something that, at least in the industrialized world, seems to become less and less frequent. Indeed, already 25 years ago, out of 171 patients with fibroids pretreated with a GnRHS, 78.4% suffered from metro-menorrhagia, but only 54.5% had Hb concentrations <12.0 g/dL.

Occasionally, the presence of large fibroids can be associated with a hematological disorder named erythrocytosis or isolated polycythemia. The pathogenesis of this phenomenon may be linked to an altered erythropoietin production, an anomaly observed in most patients with menorrhagia due to the presence of myomas. This may explain the relative rarity of cases of clinically relevant anemia despite the presence of menorrhagia.

A clear rationale exists for advocating GnRHSA pretreatment with the aim of decreasing intraoperative blood loss, since it has been documented that they produce significant alterations in uterine arterial blood flow velocity waveforms, with a parallel increase in the resistance index. In a specific investigation, uterine arterial volume decreased from 656 to 386 mL and the uterine arterial resistance index increased from 0.52 to 0.92.

Usefulness of pretreatment was documented in an RCT involving 71 hysterectomies where a significant blood loss reduction (on average 130 mL), a preoperative rise in Hb concentration, and relief of menstrual symptoms while waiting for surgery were observed following GnRHS. Lethaby et al in their systematic review concluded that blood loss is lowered...
both at hysterectomy and myomectomy; however, transfusion requirements are not modified and the improvement in postoperative hematological parameters seems small.

Some 25 years ago, an evaluation of the advantages and disadvantages of GnRHSA treatment before myomectomy led to the conclusion that, in general, surgery becomes easier, although differences for several variables were small, and 3 months after surgery, there were no major ultrasonographic differences between the two groups.

The abovementioned RCT evaluating efficacy of GnRHSA before myomectomy looked also at recurrence rates of myomas and myoma-related symptoms. After 27–38 months of follow-up, recurrence was not associated with presurgery medical therapy or preoperative uterine volume; however, it was greater when at least four myomas were resected.

**Adjuvant in laparoscopic myomectomy**

Decreasing the size of the uterus and fibroids and intraoperative bleeding can be considered two important advantages of GnRHSA pretreatment in case of laparoscopic myomectomy. This will definitely be the case in the presence of a pedunculated or subserosal myoma; unfortunately, in the case of intramural tumors pretreatment may very well make cleavage more difficult and excision more problematic.

These advantages were recognized already in the early experience of pretreatment in 150 laparoscopic myomectomies by Mettler and Semm. Subsequently, the same group compared results obtained with leuprolide and triptorelin, observing at 3 months an identical reduction of myoma size (between 10% and 50%, in 88% of both groups).

Bearing in mind that laparoscopic, compared with laparotomic, myomectomy may per se carry a greater risk of recurrence within 5 years, the question arises whether fibroid shrinkage or, if small, their visual disappearance at the time of surgery may expose patients to a higher rate of recurrence. Unfortunately, two small trials addressing the issue came to opposite conclusions.

**Adjuvant in hysteroscopic myomectomy**

In view of the increasing use of the hysteroscopic approach for myomectomy, the usefulness of GnRHSA has been carefully investigated. The combined approach has been pioneered by Donnez et al who used Ng-YAG laser and made the interesting observation of a lower vascularity in the myometrium. They suggested that after pretreatment, a two-step procedure should be carried out. This would consist of resecting first the protruding part of the tumor, followed by the intramural portion that at this stage would become accessible to the laser beam. GnRHSA therapy would then be continued for another 8 weeks.

Among the advantages, it seems that pretreatment can facilitate hysteroscopic removal by substantially reducing bleeding, thinning the endometrium, and decreasing the volume of myomas. As always, disadvantages have also been identified, such as a more difficult procedure due to the “retreat” of the mass inside the myometrium.

**Adjuvant in laparoscopic hysterectomy**

In 2003, a randomized, prospective trial of total laparoscopic hysterectomy investigated the effect of pretreatment. The study found that in the presence of large uteri (380–680 mL volume), administering a GnRHSA over 3 months can decrease uterine size, facilitating surgery by reducing operating time and blood loss.

**Long-term use**

Blocking ovarian function is an effective method of decreasing the size of myomas but has time limitation (usually 6 months) due to the hypoestrogenism that is invariably associated with the use of this class of compounds.

For this reason, in order to utilize GnRHSA for long periods of time, scientists had to first answer the question of how to continue treatment while at the same time avoid its short- and long-term negative consequences (respectively, hot flushes, insomnia, profuse sweating, and osteoporosis).

As it will be described below, today the availability of newer drugs has made the long-term use of GnRHSA unlikely and more of a historical than actual relevance.

**Preventing adverse consequences of GnRH analog treatment**

In the 1990s, several options have been evaluated, including the following:

Contemporary use of a progestin: In an early small-scale attempt, oral medroxyprogesterone acetate (MPA) was given either together or after treatment with the GnRHa. This trial clearly indicated the superiority of the sequential approach, both in terms of reduction of uterine volume and lack of regrowth by 6 months. Unfortunately, an RCT by Carr et al found that, while MPA coadministration (20 mg/day) prevented, at least partially, bone mineral loss, it also blocked fibroid shrinkage and caused a reversal in the decrease in nonmyomatous tissue volume.

Contemporary use of a superagonist analog and raloxifene: An RCT involving 100 women tested the addition of the selective estrogen receptor (SERM) raloxifene to the analog over 6 months and, as expected, found that the drug...
produced a significant reduction in the volume of the myoma even in the no-SERMs group. This effect, however, was significantly ($P<0.05$) more pronounced when both drugs were administered; in subjects treated with raloxifene, bone mineral density (BMD) and serum bone markers were unchanged.\textsuperscript{62,63}

**Use as an alternative to surgery: the add-back therapy**

In the early days, it was hoped that a GnRHSA regimen could be developed that would enable women to avoid surgery altogether. In order to achieve this goal, it would be necessary to find ways to continue therapy indefinitely.

Several modalities were tested:

*Lowering the dose of the agonist*: Broekmans et al\textsuperscript{64} attempted to maintain the positive action of the GnRHSA while minimizing negative effects. With this in mind, after an initial treatment with a full GnRHSA dosage, they lowered the dose to allow some endogenous estrogen production. With this expedient, they were able to preserve the beneficial effects of the initial full dosage without apparently affecting BMD.

*Using sequentially low-dose estrogen–progestin combinations*: Another approach has been to prolong GnRHSA treatment by adding, once shrinkage has been obtained, a low-dosage estrogen–progestin combination. In 1990, Barbieri\textsuperscript{65} proposed a theory based on the existence of a “window” of estrogen concentration that would not allow myoma regrowth but would be sufficient to substantially reduce adverse effects (see Figure 3). When this theory was applied and small quantities of an estrogen followed by a progestin (as in hormonal replacement therapy) were given, GnRHSA treatment could be continued with minimal adverse effects and no regrowth.\textsuperscript{66}

A review published in 2012 concluded that the use of add-back therapy has enabled wider application, longer duration of treatment, and an increase in compliance.\textsuperscript{67} The effectiveness of this approach at 1 year has been recently evaluated in a Cochrane review\textsuperscript{68} of 12 RCTs considered valid for the analysis, for a total of 622 subjects. With MPA, they found no evidence of an effect in relation to bone mass (BM), while there was some regrowth of the uterus. With tibolone, there was a decreased loss of BM and a better QoL was observed, although the true effect was doubtful. In addition, there might have been some increase in uterine volume and more uterine bleeding. With raloxifene, no evidence of an effect on QoL was found, while there was a beneficial action on BM, with no clear evidence of an effect on uterine volume, bleeding, or severity of vasomotor symptoms. With estradiol, no studies reported on uterine size, bleeding, or vasomotor symptoms, but its use may entail a decreased BM loss. Use of ipriflavone was associated with decreased loss of BM in a single study and no evidence of an effect on vasomotor symptoms. Finally, one study suggested that adding conjugated estrogens to GnRHA resulted in a larger decrease in uterine volume in the placebo group.

*Sequential use of high-dose progestins*: Increased expression of progesterone receptor (PR) in myomas has been considered a consequence of overexpression of estrogen receptors (ER), resulting in increased end-organ sensitivity to estradiol ($E_2$). Under these circumstances, the observation that analog therapy decreases ER concentration, whereas it increases PR expression, provides a rationale for the use of a progestin to block regrowth. Applying this paradigm, a comparative trial was carried out using high daily doses of MPA (200 mg orally for the first month, 100 mg for the second, 50 mg for the third and fourth, and 25 mg for the remaining 2 months) after the action of the analog had reduced the volume of the myomas. It was found that at the end of MPA treatment the size of the uterus was significantly increased, whereas significant myomas’ regrowth did not occur (from an average of 25.6±24.8 to 30.6±32.9 mL, $P>0.3$).\textsuperscript{69}

*Sequential use of danazol*: Good results were also obtained when the administration of two long-acting GnRHSA for 6 months was followed by an additional 6-month treatment with 100 mg of danazol daily. Myomas’ regrowth was
reduced and the increase in uterine volume was 31.2% lower than in the control group.²⁰

**Antagonist analogs**

In theory, antagonists of the GnRH would offer the advantage over superagonists of an immediate effect, avoiding the “flare-up” observed with the latter. In practice, GnRHAT deprived of fastidious side effects were not available until the early 1990s. This is the reason why the results of the first trial in patients with uterine myomas treated with a GnRHAT (called Nal-Glu) appeared only in 1993. Results indicated a mean decrease in size of 52.8%±7.3%⁷¹ (see Figure 4).

Additional small trials followed; two utilized a pre-treatment before myomectomy with a slow-releasing formulation of cetrorelix: one involved 18 subjects, and in 16 a progressive decrease in the size of the uterus (from a mean of 410.4±77.1 mL to 230±52.6 mL) was observed.⁷² The other included 20 patients, and in 16 there was a good response with the volume of the largest fibroid decreasing by 33.5%. The authors pointed out the expected rapidity of the myomas’ shrinkage with a mean reduction of 31.3% in only 14 days.⁷³⁷⁴ These early attempts were followed by a randomized, double-blind RCT involving 109 premenopausal women, divided into four groups. Groups 1–3 received placebo, 5 and 10 mg of cetrorelix on days 1, 8, 15, and 22, respectively. Group 4 received 10 mg cetrorelix on days 1 and 15. Mean (±SD) reduction of uterine volume at 1 month (measured by MRI) with placebo was 5.1%±32.1%, rising to 15.6%±20.2% with 4×5 mg and to 15.4%±34.6% with 4×10 mg. In group 4 (cetrorelix 2×10 mg) there was no response (0.65%±30.6%). In conclusion, a significant response vs placebo (P<0.05) occurred in the group administered with cetrorelix 10 mg on days 1, 8, 15, and 22.⁷⁵

In terms of mechanism of action, Chen et al⁷⁶ demonstrated the presence of mRNAs encoding for GnRHR and EGF in cultured leiomyoma cells. When cultured with cetrorelix, the number of viable leiomyoma cells was significantly (P<0.01) decreased; therefore, cetrorelix downregulates proliferating cell nuclear antigen (PCNA) and EGF expression and upregulates apoptosis in association with enhanced poly(adenosine 5’-diphosphate-ribose) polymerase expression. In addition, Britten et al⁷⁷ found that cetrorelix directly regulates type 1 collagen, fibronectin, and matrix proteoglycan production, thereby directly inhibiting extracellular matrix (ECM) production.

In 2005, the results of a small study in 19 subjects with another antagonist, ganirelix, were published.⁷⁸ Decrease in fibroid size was very rapid: median duration of treatment to achieve maximal reduction was 19 days, with a range of 1–65 days. Reduction in fibroid volume at MRI was −29.2% (range −62.2% to 35.6%) and −42.7% (−77.0% to 14.1%) at ultrasound. Comparable uterine size reduction in uterus size was −25.2% (−63.6% to 28.9%) at MRI and −46.6% (−78.6% to −6.1%) at ultrasound.

**Orally active antagonists of the gonadotropin-releasing hormone receptor**

The perceived need for nonpeptidic, orally active, potent GnRHR blockers led over the last two decades to an active search for compounds capable of inhibiting the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) and, through this mechanism, of reducing the levels of circulating estrogens in normal women.

The search identified a number of potential candidates, such as derivatives of quinolone-6-carboxamides, dimethylphenyl-tryptamine, mono- and di-amino pyrimidine, 2-phenylimidazol-pyrimidin, arylirimidine, aminomethyl-imidazol-pyrimidone, arylmethyl-methyluracils, O-alkyl quinolone, benzimidazole-5-sulfonamides, piperazinylbenzimidazoles, propargylated benzene core, and pyrimidinyl-phenyl-3-methoxyurea. A summary of the situation was presented in 2008.⁷⁹

Additional compounds have been synthesized since, although only a few are being developed for use in subjects with fibroids. These will be described in detail.

**Elagolix**

In 2003, Zhu et al⁸⁰ reported that a series of novel uracil derivatives [1-arylmethyl-3-(2-aminoethyl)-5-aryluracil]...
showed potent anti GnRHR activity. The group started a systematic evaluation of this class of compounds,\textsuperscript{51-86} and in 2008, Chen et al\textsuperscript{87} published the discovery of a potent and orally available nonpeptide antagonist of the GnRHR. Chemically, the compound is an uracil-phenyl-ethylamine bearing a butyric acid and was given the code name NBI-42902. It belongs to a class of compounds producing inhibition of CYP/CYP450 3A4 (CYP3A4), an enzyme member of the CYP/CYP450 superfamily of monoxygenases, encoded by a gene on chromosome 7q21.1 that catalyzes the synthesis of cholesterol, steroids, and other lipids. The group aimed at improving the CYP3A4 inhibition liability of these uracils, while maintaining their antagonistic action on GnRHR and focused on R-4-\{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[ trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino\} butyric acid sodium salt, later coined as “elagolix”. Its oral administration suppressed LH production in castrated macaques, making it suitable for potential use in humans.

In fact, even before the publication of the compound’s identification, Struthers et al\textsuperscript{88} reported on the safety, pharmacokinetics, and inhibitory effects on gonadotropin secretion of NBI-42902 in 56 postmenopausal women with FSH levels >40 IU/L, and a BMI index within 20% of ideal values. Volunteers were administered orally 5, 10, 25, 50, 75, 100, 150, or 200 mg of the compound. They found that the medication was well tolerated, and it quickly reduced serum LH concentrations in a dose-dependent fashion. Suppression of FSH was less pronounced.

The following year, the group published a first in vitro and in vivo pharmacological characterization of the novel antagonist, reporting that titrated NBI-42902 binds with high affinity to a single class of binding sites and can be displaced by a range of peptide and nonpeptide GnRHR ligands. In vitro NBI-42902 acts as a potent functional competitive antagonist of GnRH-stimulated inositol phosphate accumulation, Ca(2+) flux, and extracellular signal-regulated kinases 1/2 activation. They concluded that the compound possessed all the pharmacological characteristics required for a nonpeptide GnRHR antagonist to have clinical applications.\textsuperscript{89}

Additional information on elagolix was published in 2009.\textsuperscript{90} Briefly, this investigation demonstrated that the compound was well tolerated and became rapidly bioavailable after oral administration, with median time of maximum plasma concentration (T_{max}) values ranging from 0.5 to 1 hour, reaching peak plasma concentrations from 55.5±23.8 to 1,504±492 ng/mL in the 25- and 400-mg groups, respectively. It produced a rapid decline in circulating levels of gonadotropins, consistent with the rate of clearance of LH, suggesting an immediate blockade of the GnRHR. FSH levels followed a similar pattern, although they were suppressed to a lesser extent and the decline was slower. With doses of at least 50 mg/day, circulating levels of E\textsubscript{2} also decreased and at the dosage of 50–200 mg/day or 50 mg twice daily, they remained low (17±3 to 68±46 pg/mL) in most subjects during late follicular phase. Importantly, effects were rapidly reversed after discontinuation. Elagolix was well tolerated at all doses; among side effects, worthy of mention are headache, abdominal pain, and hot flashes.

Because of the good results obtained with GnRHA in the treatment of endometriosis, the first clinical application of elagolix was in subjects with this condition, where the effects of the antagonist (150 mg every day, 75 mg twice a day) were compared to those obtained with subcutaneous injections of depot-medroxyprogesterone acetate (DMPA) over 24 weeks of treatment and 24 weeks of posttreatment follow-up.\textsuperscript{91} The study collected information on the effects of the medication on a number of parameters of interest for all subjects treated with elagolix. First, it was found that all treatments induced minimal mean changes in BMD at 24 weeks as follows: elagolix 150 mg, –0.11–0.47%; elagolix 75 mg, –1.29–1.2%; and DMPA 0.99–1.29% in the spine and total hip, respectively, with similar or lower changes at week 48 posttreatment. Circulating concentrations of N-telopeptide underwent minimal changes in all treatment groups. In terms of E\textsubscript{2}, circulating levels, they were measured pretreatment on days 2–7 after the onset of menses and were comparable in the two elagolix groups (41.1 and 39.1 pg/mL). During treatment (from weeks 4 to 24) median concentrations ranged from 36 to 63 pg/mL in the elagolix 150 mg/day group and from 23 to 31 pg/mL in the elagolix 75 mg twice a day group. During the posttreatment weeks, in both elagolix groups levels rapidly increased, consistent with a return of normal menstrual cycles. Interestingly, during the study, there were eight pregnancies among women treated with elagolix: three that occurred during the treatment period and five during the posttreatment period, ranging between 2 and 12 months after the last dose.

An important feature of this study was the safety assessment. As reported already, the most common adverse events in subjects treated with elagolix were headache, nausea, and nasopharyngitis. Only three patients in the elagolix 150 mg/day group and three in the elagolix 75 mg twice a day group experienced side effects that were considered serious. During the 1-month screening pretreatment period, one or more episodes of hot flash were experienced by 47.6% and
39.3% of the patients randomized to receive elagolix. During the 6-month treatment period, the percentage of elagolix-treated subjects experiencing one or more episodes of hot flash rose to 71.1% and 82.1%, respectively.

The good results obtained in this first large study led by Ezzati and Carr\textsuperscript{2} concluded that elagolix may become a valuable addition to the armamentarium of pharmacological agents to treat endometriosis-related pain and, indeed, two recently published double-blind, randomized, 6-month Phase III trials seem to confirm this conclusion. The two trials evaluated the effects of elagolix, 150 mg/day and 200 mg twice daily, compared with placebo in women with surgically diagnosed endometriosis and pain.\textsuperscript{93} Of interest is the observation that for all patients treated with elagolix, those who received it had higher rates of hot flushes (mostly mild or moderate), higher levels of serum lipids, and greater decreases from baseline in BMD than those who received placebo. Finally, these good results were confirmed in a very recently published long-term study of 569 patients with endometriosis. Treatment with elagolix produced a reduction in dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia.\textsuperscript{94} The pharmacokinetics and pharmacodynamics of elagolix have been further elucidated in a very recent report of a double-blind RCT with multiple ascending doses (150 mg once daily or 100, 200, 300, or 400 mg twice daily) or placebo administered for 21 days to 45 healthy premenopausal women.\textsuperscript{95} This investigation confirmed that elagolix is rapidly absorbed after ingestion, reaching maximum concentrations between 1 and 1.5 hours, with a half-life of 4–6 hours. Dose-dependent suppression of E\textsubscript{2} was observed, with maximum suppression being achieved with 200 mg twice daily. Also, the suppression of FSH, LH, and E\textsubscript{2} occurred within hours of the first day of administration. Dose-dependent suppression of FSH and LH was also observed, with maximal or near-maximal suppression achieved with the dose of 200 and 300 mg twice daily. Even at lower doses (≥100 mg twice daily), P concentrations remained at anovulatory levels throughout the 21 days. It seems, therefore, that elagolix allows for modulation of gonadotropin and ovarian hormone concentrations, with a partial suppression at lower doses and nearly full suppression at higher ones.

Following these encouraging results, elagolix has been now tested in premenopausal women with myomas and heavy menstrual bleeding (menstrual blood loss [MBL] >80 mL per cycle) in a three-prong trial: elagolix vs placebo and elagolix plus low-dose estrogen/progestogen add-back therapy.\textsuperscript{96} This Phase II proof-of-concept study has been conducted in 271 women with a mean age of 41.8 years. Of the randomized women (elagolix alone, n=160; placebo, n=50; elagolix with add-back therapy, n=61), 228 completed the 3-month treatment period. The elagolix-alone arm tested the following dosages: 100, 200, 300, all twice a day and 400, 600 mg daily (all but the 600 mg group were placebo controlled). The third group received either elagolix 200 mg twice daily plus, as add-back therapy, continuous daily E\textsubscript{2} 0.5 mg/norethisterone acetate (NETA) 0.1 mg, or elagolix 300 mg twice daily plus E\textsubscript{2} 1 mg continuously and cyclical P 200 mg.

The least squares mean percentage change in MBL from baseline to day 28 was significantly greater with elagolix alone (range, −72% to −98%; dose-dependent reduction was highest with 300 mg twice daily) vs placebo (range, −8% to −41%); mean percentage changes with add-back regimens were −80% to −85%. Overall, adverse events were dose independent (elagolix alone, 70.0%–81.3%), but lower with placebo (56.0%) and add-back regimens (55.6%–70.6%). Hot flush was the most common side effect (elagolix alone, 45.5%–62.5%; placebo, 12.0%; add-back regimens, 18.5%–26.5%; Figure 5).

In conclusion, this preliminary study documented that Elagolix significantly reduced heavy menstrual bleeding in women with fibroids; in addition, low-dose add-back regimens substantially reduced flashing.

**SKI-2670**

This new, nonpeptidic, orally available GnRHR blocker\textsuperscript{97} (code-named SKI-2670) has been recently pharmacologically characterized both in vitro and in vivo through measurement of its binding affinity and antagonistic activity for GnRHR. In castrated monkeys at equivalent doses, a single administration lowered serum LH levels more significantly and with a longer duration compared with elagolix. In addition, in intact female monkeys, SKI-2670 suppressed serum levels of both gonadotropins and ovarian hormones, whereas elagolix suppressed only serum LH levels.

**SKI-2496**

Another orally available GnRHR blocker based on a uracil scaffold has recently been synthesized and characterized.\textsuperscript{98} It was given the code name of SK-2496 and it exhibits a highly selective antagonistic activity toward human GnRHR, as well as an inhibitory effect on GnRH-mediated signaling pathways. It has improved bioavailability and superior gonadotropic suppression activity compared with elagolix, thus representing a promising candidate for an orally available GnRHR blocker.
Relugolix (TAK-385)

The identification of a fourth orally active GnRHR blocker, relugolix (code named TAK-385) with high affinity and potent antagonistic activity for human and monkey GnRHR was reported by Miwa et al in 2011. In female knock-in mice, it induced constant diestrus phases within the first week, decreased the uterus weight to ovariectomized levels, and downregulated GnRHR mRNA in the pituitary after 4 weeks.100

OBE-2109

The human pharmacodynamics and safety of a fifth nonpeptide inhibitor (code-named OBE-2109) have just been published, both alone and in combination with E₂ plus NETA add-back therapy. When given alone at the dose of 100 and 200 mg, within a month OBE-2109 reduced circulating E₂ levels, respectively, to a median of 19.5 and 3.2 pg/mL and induced amenorrhea. On the other hand, given in combination with add-back therapy, it produced levels ranging between 25 and 40 pg/mL, but bleeding control was partially impaired.101

Selective progesterone receptor modulators (SPRMs)

Myomas’ growth is highly dependent on the presence of estrogens and, indeed, these tumors are exceptional before puberty and regress after the menopause.102

Progesterone plays also a role exerting a dual action: on the one hand it stimulates myoma growth through upregulating EGF and Bcl-2 expression; on the other, it inhibits growth through downregulation of IGF I expression in the cells.29 The beneficial effect on fibroid growth can be seen during pregnancy when often they remain unchanged and may even regress or undergo the so-called red degeneration.24

Evidence for more complex mechanisms came from studies with GnRHA where it was shown that the addition of a progestin at the beginning of treatment prevents fibroid shrinkage.60,61,103 Additional information came from morphological studies showing a higher mitotic index in myomas during the secretory phase.104

Today, it is widely accepted that a wide number of factors play a role in myoma growth, including EGF, IGF I and II,
and growth hormone with P acting as a stimulant of these growth factor expressions.\textsuperscript{105}

In view of this new evidence a call for rethinking the complex mechanism of fibroids’ growth and regression has been made\textsuperscript{106} and a rationale exists for using the new class of compounds called “antiprogestins”, today more correctly coined as “SPRM”. Several of them do not have “pure” antiprogestins activity, but it seems that they act through the suppression of the expression of the PR gene.\textsuperscript{107} A major synthetic program of these compounds was carried out in the last decade of the twentieth century by the Contraceptive Development Branch (CDB) of the Center for Population Research at the US National Institutes of Health (US-NIH).\textsuperscript{108} Among others, this led to the development of proellex, telapristone, and ulipristal.

**Mifepristone (MFP)**

MFP, initially code-named as RU486, represents the prototype SPRM, being the first to have been synthesized and utilized clinically.

The compound has been shrouded in a never-ending controversy because its first utilization has been for the medical interruption of gestation.\textsuperscript{109}

A pioneering trial in 10 patients\textsuperscript{110} demonstrated that 50 mg of MFP produced a significant, but diverse reduction in myomas’ size (varying between 0% and 87%). Subsequently, the dosage was lowered to 25 mg daily with the same results.\textsuperscript{111} In an early comparative trial, MFP and leuprolide acetate were equally effective in decreasing uterine volume and blood flow to the uterus.\textsuperscript{112} Due to a series of circumstances, no progress was made for a decade and a search in 2004\textsuperscript{113} identified only six clinical trials with MFP for a total of 166 subjects, all with good results. Using low (5 mg) and ultralow (2.5 mg) daily MFP doses, an average reduction of 47% and 11% in uterine volume was obtained.\textsuperscript{114,115} With 10 mg, volume of the uterus, myomas, and largest fibroid declined by \textgreater{}25% and the amount of blood loss by almost 95%; Hb increased from 9.5 to 11.2 g/dL and dysmenorrhea was completely relieved in 80% of the subjects.\textsuperscript{116}

Over the last decade, several additional studies have been carried out using daily dosages ranging from 50 to 10 mg, always reporting good results.\textsuperscript{117–121}

A systematic Cochrane review of 2012\textsuperscript{122} found only three truly RCTs of MFP vs other medical therapies or placebo, involving 112 participants with different dosages, concluding that MFP use relieves heavy menstrual bleeding, although there was no conclusive evidence for an effect on the fibroid volume. Another metaanalysis, published in the following year,\textsuperscript{123} included 11 RCTs (testing doses between 2.5 and 25 mg for 3–6 months and involving 780 subjects) and reached the opposite conclusion: MFP is effective in reducing uterine and fibroid volume, hypermenorrhea, MBL, pelvic pain, pelvic pressure, anemia, and dysmenorrhea. At this stage, a group in Spain concluded that a 5 mg dose was preferable to 10 mg.\textsuperscript{124,125}

Recently, different administration schedules were evaluated in two Indian trials, using weekly or biweekly doses of 50 mg claiming good results.\textsuperscript{126,127} Using the vaginal route for the administration of 10 mg daily of MFP, treatment significantly reduced the volume of fibroids.\textsuperscript{128}

In terms of mechanism of action, Chinese investigators have suggested that EGF mRNA levels in myomas seem controlled by P and MFP can inhibit EGF gene expression in myomas.\textsuperscript{129} Also, PR and its mRNA are overexpressed in fibroids and MFP may act by suppressing expression of the PR gene.\textsuperscript{130} The molecular basis of volume reduction in women treated with 50 mg MFP every other day was also investigated showing that the glutathione pathway was the most significantly altered with an overexpression of the glutathione-s transferase-Mu-1 (GSTM1) gene in good responders compared with nonresponders. Deletion of the GSTM1 in leiomyoma biopsies was found in 50% of the MFP-treated subject.\textsuperscript{131}

**Asoprisnil (ASP)**

ASP, code-named J867, and its major metabolite (code-named J912), represent a class of PR ligands with partial agonist and antagonist activities in vivo.\textsuperscript{132} Its early clinical application to the medical treatment of fibroids was reviewed by Chwalisz et al.\textsuperscript{133} The same group later published the results of a multicenter RCT using doses of 5, 10, and 25 mg daily. ASP significantly suppressed both the duration and intensity of uterine bleeding, inducing amenorrhea in a dose-dependent fashion (28%, 64%, and 83%), increasing Hb concentration, and significantly decreasing fibroid and total uterine volumes in the 25 mg group.\textsuperscript{134}

Chen et al\textsuperscript{135} using an in vitro model produced evidence that ASP can decrease the number of myoma cells, the PCNA-positive rate, its protein expression, and selectively induce apoptosis in uterine leiomyoma cells without affecting normal myometrial cells. It can also increase the expression of PR-B, but not PR-A. In addition, in cultured myoma cells, ASP can selectively downregulate the expression of EGF, IGF I, transforming growth factor and their receptors;\textsuperscript{136} activate tumor necrosis factor-related apoptosis-inducing ligand-mediated signaling pathway; elicit stress-induced apoptosis\textsuperscript{137} and endoplasmic reticulum stress;\textsuperscript{138} selectively reduce collagen deposition in cultured leiomyoma cells, but not in normal myometrial cells through a decreased collagen
synthesis.\textsuperscript{139} Finally, ASP does not induce proliferation of uterine tissues and does not suppress the tumor suppressor gene PTEN expression.\textsuperscript{140}

Under the action of ASP, there is an alteration of uterine spiral arteries morphology leading to suppression of bleeding\textsuperscript{141} and a statistically significant reduction of genes in the IL-15 pathway, known to play a key role in uterine natural killer (uNK) development and function.\textsuperscript{142}

In 2005, due to abnormal findings in endometrial biopsies of treated women (see section “Asoprisnil” under “Effects of SPRM on the endometrium” in this article), clinical trials with ASP were suspended by the manufacturer.

**Proellex (telapristone)**

In 2002, Attardi et al\textsuperscript{143} examined the in vitro properties of one of the compounds synthesized by the US-NIH (code name CDB-4124), later named as proellex, or telapristone, and its mono-de-methylated metabolite, code named CDB-4453. Both the SPRM bind with high affinity to rabbit uterine PR, do not exhibit agonist activity, and possess considerably lower antiglucocorticoid action than MFP. CDB-4124 selectively inhibits proliferation and induces apoptosis in myoma, but not in normal myometrial cells,\textsuperscript{144} although a subsequent investigation did not find any significant apoptosis in cultured fibroid cells, suggesting that apoptosis may not be the main pathway responsible for CDB-4124-induced fibroid shrinkage.\textsuperscript{145}

At present, it does not seem likely that the manufacturer wishes to proceed further to apply Proellex to the medical treatment of myomas. In addition, during 2017, the US-FDA told the manufacturer that a new trial was needed to prove that using the oral route to administer the drug is safe. This prompted the manufacturer to consider refocusing on the vaginal route to deliver telapristone for the treatment of endometriosis.\textsuperscript{146}

**Ulipristal (UPA)**

UPA, code-named CDB-2914 or VA-2914, is the most widely utilized and most promising SPRM available today. A practical method for its large-scale synthesis was published in 2000,\textsuperscript{147} starting a series of investigations on its pharmacological\textsuperscript{148} and clinical indications.\textsuperscript{149}

UPA inhibits the proliferation of cultured leiomyoma cells by downregulating PCNA and C/EBP-2 expression and by upregulating cleaved caspase-3 and poly (ADP-ribose) polymerase expression.\textsuperscript{150} It also downregulates VEGF, adrenomedullin and their receptor contents, and specifically modulates PR isoform contents in cultured leiomyoma cells.\textsuperscript{151,152}

The induction of apoptosis by UPA in uterine fibroid cells has been confirmed in vivo in two groups of six and five subjects harboring leiomyomas, using daily doses of 5 and 10 mg UPA. Results were compared to those obtained in 17 women treated with a GnRHSA and 10 subjects with no hormonal treatment. It was found that apoptosis was present in a significantly higher proportion of patients treated with UPA compared with the GnRHSA and was absent in controls.\textsuperscript{153} In vitro, UPA decreases inhibin-βA subunits, follistatin, activin receptor type IIB and activin receptor-like kinase 4 mRNA expressions and blocks the activin A-induced increase in fibronectin or VEGF-A mRNA expression.\textsuperscript{154} It shows good oral bioavailability and a half-life allowing one single oral administration per day; being a steroid, UPA is a substrate for CYP3A4, although it is not an inducer or inhibitor of the CYP system.\textsuperscript{155}

Starting in 2008, the selective action of UPA on fibroids was tested clinically; first, in a dose-finding study involving 22 subjects at the daily dose of 20 and 10 mg, obtaining a significant reduction in myoma’s volume of 36% and 21%, respectively.\textsuperscript{156} Further results were published 3 years later in 28 women treated for 3–6 months, with a second 3-month course also offered. In controls the total volume of fibroids increased by 7%, whereas it decreased by 24% and 17%, respectively, in the 20 and 10 mg groups. During the second 3-month period, fibroid volume further decreased by 11%. Amenorrhea occurred in 20/26 treated women and Hb concentration improved together with the subjects’ QoL.\textsuperscript{157}

In the subsequent years, multicenter clinical investigations were carried out to prove the efficacy of UPA in the medical management of myomas. They were labeled “PEARL I–IV”.\textsuperscript{158} A first trial\textsuperscript{159} presented the results of a 13-week, three-prong investigation of subjects with anemia (Hb≤10.2 g dL) due to excessive blood loss. UPA was administered at the dose of either 5 or 10 mg/day to two groups of 96 and 98 patients, respectively; a third group of 48 women received placebo. Treatment with UPA resulted in a proper control of bleeding in 91% and 92% of the subjects vs 19% of those receiving placebo (P<0.001). Uterine volume decreased by 21% and 12%, respectively, and increased by 2% in controls.

A second, double-blind, noninferiority trial\textsuperscript{160} compared the action over 3 months of oral 5 or 10 mg UPA to that of a monthly injection of 3.75 mg leuprolide acetate in 307 subjects. Bleeding control was achieved in 90% of women receiving UPA 5 mg, 98% of those given UPA 10 mg and in 89% of patients injected with leuprolide acetate.
The third study tested the feasibility of long-term (up to 1 year) UPA treatment of symptomatic myomas in three groups totaling 209 patients.161 One group received UPA 10 mg daily, immediately followed by a 10-day double-blind administration of NETA or placebo. This resulted in myoma’s shrinkage by 63%, 67%, and 72% at 6, 9, and 12 months, respectively. The authors concluded that the use of NETA did not affect fibroid volume or endometrial histology.

Finally, the fourth trial dealt with the effectiveness and safety of 212-week cycles of 5 or 10 mg UPA daily in 451 women.162 They observed control of excessive bleeding in >80% of subjects, a mean reduction in fibroid volume of 54% and 58%, respectively, and an improvement in pain symptom and overall QoL.

A systematic metaanalysis of the effects of UPA in women harboring fibroids was conducted in 2016;163 it included four RCTs (three comparing the drug with placebo and one comparing it with a GnRHA) for symptomatic relief. The trials reported improvement in excessive uterine bleeding as evidenced by the very significant attainment of amenorrhea (P<0.00001). An improved QoL parameters and reduction in fibroid size were noted in the UPA group.

A major advancement was made when an international group carried out a double-blind, RCT with on-and-off four 12-week courses of UPA (10 and 5 mg daily) for the long-term treatment of fibroids. Each treatment course was separated by a drug-free period of two spontaneous menstrual bleeds164 (see Figure 6). The study confirmed the efficacy of UPA in controlling pain and bleeding, in reducing fibroid volume, and in markedly improving QoL of the patients, even during the off-treatment intervals. No significant changes in laboratory parameters were observed, documenting the effectiveness of UPA as an alternative to surgery.

The abovementioned international group has now extended their study, using the 10 mg dosage, to assess long-term safety over ~4 years of extended repeated 3-month courses of UPA in 64 premenopausal women.165 No changes in the number and type of laboratory results outside the normal ranges were observed and, overall, incidence of adverse events with increasing treatment courses were reported in

![Figure 6](https://www.dovepress.com/)

**Figure 6** Administration schedule for ulipristal in the treatment of uterine myomas.

**Note:** Reprinted from Fertility and Sterility, Vol 105(1), Donnez J, Donnez O, Matule D, et al, Long-term medical management of uterine fibroids with ulipristal acetate, Pages 165–173, Copyright (2016), with permission from Elsevier.164

**Abbreviations:** PA, ulipristal acetate; PBAC, pictorial blood assessment chart.
16%, 19%, 14%, and 9% of the subjects, during treatment courses 5, 6, 7, and 8. The only frequently reported adverse events were headache and hot flushes.

Finally, the use of UPA can facilitate surgery or, following reduction of fibroid volume, improve the surgical approach and restore normal preoperative Hb. In view of the widespread use of UPA, now marketed as Esmya, and following reports of rare serious liver injury, including liver failure, the EMA Pharmacovigilance Risk Assessment Committee (PRAC) carried out a full evaluation and concluded that UPA may have contributed to the development of some of the reported cases. The PRAC, therefore, recommended measures to minimize liver injury, including contraindication when liver problems are known and liver tests before, during, and after stopping treatment.

Notwithstanding the warning, on June 2018, EMA’s Committee for Medicinal Products for Human Use has recommended granting marketing authorization for UPA in the preoperative treatment of uterine myomas.

**Effects of SPRM on the endometrium**

PR modulators induce unique effects on the endometrium that cannot be assessed using the criteria usually employed for dating it. To try to elucidate this phenomenon, a group of pathologists developed a “Dictionary of Endometrial Biopsy Diagnoses for Clinical Trials with SPRMs” to supplement existing conventional descriptive criteria. This situation prompted the US-NIH to sponsor a study to evaluate endometrial specimens from women receiving four different SPRM, concluding that under treatment endometrium usually appears as inactive or normally cycling, with no sign of premalignant lesions. At the same time, a singular picture consisting of an asymmetry of stromal and epithelial growth with cystic dilated glands and a mix of mitotic and secretory effects was observed in a subset of cases. One unique feature was “that the physiological separation between estrogen- and progesterone-induced changes, in which progesterone downregulation of ERs prevent co-stimulation of both pathways, was perturbed in the PRM-exposed patients”. These changes were coined “PRM-associated endometrial changes” (PAEC) and may be identified and visualized at ultrasound.

SPRM have different progestational and antiprogestational actions and therefore their endometrial effects must be considered separately.

**Mifepristone**

At the beginning of the twenty-first century work on MFP was resumed; initially conflicting results were reported: in one trial, no endometrial hyperplasia was noted in any participant, whereas in another, abnormalities described as “endometrial hyperplasia without atypia” were found. It was immediately pointed out that SPRM “do not cause endometrial hyperplasia, although they do produce endometrial appearances that are quite unusual”. For this reason, pathologists not familiar with these unique changes may mistake them as “hyperplasia”. A comparison of endometria from women treated with low-dose MFP and normal subjects evidenced the presence of nonsynchronous endometrium, large fluid-filled glands, and abnormal blood vessels, with cell injury and cell death in capillary endothelial cells, but no detectable effects on their mRNA expression for several markers.

The already-mentioned Cochrane Review concluded that pooled data suggest that MFP induces an abnormal endometrial histology compared with placebo OR 31.65; 95% CI 4.83 to 207.35) but acknowledged that this appears different from the sometime premalignant endometrial hyperplasia associated with unopposed estrogen treatment. In addition, no significant differences were observed in the rate of atypical endometrial hyperplasia between the MFP-treated groups and controls.

**Proellex (telapristone)**

Although the development of this SPRM has not been pursued for the treatment of women harboring fibroids, its effect on the endometrium has been evaluated in samples from 58 premenopausal women treated with daily oral doses of 12.5, 25, or 50 mg. At 3 or 6 months, 103 out of 174 biopsies showed a number of histological changes similar to those observed with other compounds: the endometrium was generally inactive or atrophic with a superimposed formation of cystic dilated glands and secretory changes coexisting with mitoses and apoptotic bodies, but no hyperplasia. At ultrasound, the presence of an increased endometrial thickness could also be detected.

**Asoprisnil**

The already reported, early investigation of endometrial changes under the influence of ASP evidenced a unique pattern consisting of “partially developed secretory glandular appearances and stromal changes”. These consisted in low mitotic activity in glands and stroma, unusually thick-walled muscular arterioles, and prominent aggregations of thin-walled vessels in the stroma. The investigators concluded that such a nonphysiologic secretory effect was specific of ASP. A further double-blind, RCT attempted to elucidate the mechanism through which ASP suppresses endometrial bleeding; they identified a statistically significant reduction of genes in the so-called IL-15 pathway, involved in uNK...
function, with a major reduction in immunostaining of uNK cell marker CD56 \((P<0.001)\). These findings are considered “a missing link in the complex interplay among endometrial stromal cells, uNK, and spiral arteries affecting physiologic and pathologic endometrial bleeding”\(^\text{142}\).

The action of ASP was also evaluated in vitro, providing novel evidence for its growth inhibitory effect, antiproliferative, proapoptotic, and antiangiogenic actions on cultured leiomyoma cells in the absence of comparable effects on cultured normal myometrial cells.\(^\text{176}\) ASP modulated the ratio of PR isoforms \(A\) and \(B\) in cultured leiomyoma cells; decreased the cell viability; suppressed the expression of growth factors, angiogenic factors, and their receptors and induced apoptosis. Finally, it suppressed types I and III collagen synthesis.

**Ulipristal acetate**

Early investigations on the in vivo effects of UPA identified the presence of the endometrial anomalies that seem a peculiarity of all SPRM. As for other compounds, they were initially labeled “hyperplasia”. Interestingly, a preliminary investigation using 5- and 10-mg daily doses to 46 healthy subjects did not evidence any case of endometrial hyperplasia.\(^\text{177}\) A second study checked endometrial vascularization, fibrillar matrix, and VEGF-A expression and found that UPA does not alter any of these parameters.\(^\text{178}\) Further investigations found that during follicular phase, UPA causes a significant increase in the expression of a protein involved in chondrocyte differentiation (called Indian Hedgehog) and in genes involved in its signaling.\(^\text{179}\) in rhesus macaques, UPA administered intraterus induces endometrial atrophy and amenorrhea, although some glandular cysts were found.\(^\text{180}\)

In humans, UPA induces an inactive glandular epithelium with occasional subnuclear vacuolization, mitosis, and apoptosis. At the same time, glandular architecture is altered and extensive cystic dilatations are present, as well as abnormal stromal vessels. Hyperplasia was found in one case and in four subjects the formation of polyps was also observed; importantly, 6 months after treatment, the endometrial histology returned to normal in the vast majority of the patients.\(^\text{181}\)

The already mentioned PEARL II trial measured a mean endometrial thickness of 9.4 mm with 5 mg and 10.7 mm with 10 mg, without any alteration that could be of clinical concern, with only one case of simple hyperplasia.\(^\text{160}\) The long-term study\(^\text{161}\) confirmed the presence of nonphysiological, benign endometrial histological alterations (both cyst formation, epithelial and vascular changes). These were observed at different lengths of treatment in 18.0%, 21.4% and 16.3% of biopsies; following discontinuation, changes persisted in 9.1% of biopsies.

The safety of this treatment regimen has now been summarized, concluding that published reports of RCTs have demonstrated that, whereas UPA induces endometrial changes, they are both benign and reversible.\(^\text{182}\)

Recently, a Cochrane review tried to draw conclusions from 10 studies with a total of 1,450 participants’ existing data\(^\text{183}\) and made the following points:

- All studies described the presence of PAEC in 41%–78.8% of all patients.
- After discontinuation, in three studies the percentage of PAEC decreased from 62% to 0%, 78.8% to 0%, and from 59% to 6%–7%.
- In 0.4% of all subjects, endometrial hyperplasia was reported during or after UPA: simple hyperplasia (five cases) and simple atypical hyperplasia that resolved into benign secretory endometrium by the end of the treatment (one case). One endometrial adenocarcinoma was reported, but it was already present at the baseline biopsy.
- Transvaginal ultrasound or MRI showed a transient increase of endometrial thickness during treatment, which returned to normal within a few weeks after discontinuation.

In conclusion, whereas the unique nature of endometrial changes produced by SPRMs on the endometrium is undeniable, its significance, possible long-term effects, and therefore regulatory aspects are still open to debate and to lack of agreement.

To minimize the occurrence of these changes one might try a mixed regimen using first a GnRHA and, after obtaining a proper volume reduction and an inactive endometrium, begin treatment with an SPRM.\(^\text{184}\)

**A look at the future**

The consequences of the advent of this new class of compounds for the medical management of fibroids have been analyzed by several groups with regard to the most promising of them, UPA. Specifically, it has been pointed out that the choice of a given treatment is influenced by a number of factors, including the severity of symptoms, myomas’ characteristics, age, and a wish to preserve fertility. In this context, there is a real need for alternatives to surgical intervention, and today these exist through the long-term use of SPRM.

In spite of these advances, the time has also come to explore novel strategies for the management of uterine fibroids. One such new avenue has been recently evaluated by Islam et al\(^\text{185}\) who observed that ECM forms the bulk structure of fibroids, with the ECM-rich rigid structure possibly contributing to abnormal bleeding and pelvic pain. For this
reason, a possible novel approach could be directly or indirectly targeting ECM. The presence of elevated levels of collagens, fibronectin, laminins, and proteoglycans can induce the so-called mechanotransduction process through which cells convert a mechanical stimulus into an electrochemical activity. This will result in an altered bidirectional signaling between myoma cells and the ECM. Although several antiproliferative agents are already available for the treatment of fibroids, in the future ECM should be considered as a crucial target.

Overall reviews
Two recent reviews dealt with the role of SPRM in the long-term medical treatment of hormone-dependent conditions like uterine fibroids, concluding that this class of compounds has emerged as a valuable option capable of offering women effective long-term medical management and avoid surgery altogether.

The first focused on pharmacological effects on the endometrium, their antiproliferative action, and their suppression of bleeding. The second is a Cochrane review of RCTs evaluating their effectiveness. The metaanalysis involved a total of 11 studies comprising 1,021 participants: 685 received an SPRM (MFP, UPA, and ASP). Use of an SPRM vs placebo resulted in improvements in fibroid symptom severity (mean differences [MD] –20.04 points, 95% CI –26.63 to –13.46) and in health-related QoL (MD –22.52 points, 95% CI 12.87 to 32.17). Treatment resulted in reduced MBL, but the effect was considered small (standardized mean differences –1.11, 95% CI –1.38 to –0.83) and in higher rates of amenorrhoea (2.9% in the placebo group vs 23.7% to 96.1% in the SPRM group). No conclusion was reached for improvement in pelvic pain owing to variability in the estimates. No difference in effectiveness was found when an SPRM was compared to leuprolide acetate, except that endometrial changes were more common after SPRM therapy than after leuprolide treatment (OR 10.45, 95% CI 5.38 to 20.33).

Antiestrogens
In 2003, an RCT compared the ability to reduce fibroid growth before hysterectomy of the antiestrogen fulvestrant (as an intramuscular injection of 50, 125, or 250 mg) with that of the GnRHA goserelin (as a subcutaneous injection of 3.6 mg), or an injection-matched placebo, once every 4 weeks. A total of 307 women diagnosed with uterine fibroids requiring hysterectomy were enrolled over a period of 12 weeks.

Goserelin significantly reduced fibroid growth and endometrial thickness compared with placebos, whereas fulvestrant did not significantly alter fibroid volume or endometrial thickness or change endpoints such as endometrial histology or vaginal bleeding.

It seems, therefore, that at dosages similar to those commonly utilized for treatment of breast cancer in postmenopausal women, fulvestrant does not significantly inhibit fibroid growth.

Overall considerations
The usefulness of the various treatment options on preoperative medical therapy before surgery for uterine fibroids up to 2017 has been the object of a recent Cochrane review by Lethaby and coll. Their search found 38 RCTs meeting their criteria and involving 3,623 subjects.

The following categories of trials were analyzed:
- GnRHA vs no pretreatment (n=19)
- GnRHA vs placebo (n=8)
- GNRHA vs progestin, SPRM, SERM, dopamine agonists (n=7)
- SPRM vs placebo

In general, studies were considered of low or moderate quality and often open to criticism.

Pretreatment with GnRHA vs no pretreatment or placebo was associated with reductions in both uterine (MD –175 mL, 95% CI –219.0 to –131.7) and fibroid volume (MD 5.7 mL to 155.4 mL) and increased preoperative Hb (MD 0.85 g/dL, 95% CI 0.7 to 1.1). Concomitantly, there was an increase of hot flushes (OR 7.68, 95% CI 4.6 to 13.0).

In the case of hysterectomy, pretreatment with GnRHA reduced duration of surgery (~9.59 minutes, 95% CI 15.9 to ~3.28) and of blood loss (MD 25 mL to 148 mL), led to a lower utilization of blood transfusions (OR 0.54, 95% CI 0.3 to 1.0), and fewer postoperative complications (OR 0.54, 95% CI 0.3 to 0.9).

With myomectomy, preuse of GnRHA reduced intraoperative blood loss (MD 22 to 157 mL). There was no clear evidence of a difference in blood transfusions (OR 0.85, 95% CI 0.3 to 2.8) or postoperative complications (OR 1.07, 95% CI 0.43 to 2.64).

Preuse of GnRHA vs other medical therapies induced a greater reduction in uterine volume (~47 to ~20 and ~22% with 5 mg and 10 mg UPA), at the cost of increase in hot flashes (OR 12.3, 95% CI 4.04 to 37.48). There was no clear difference in bleeding (UPA 5 mg: OR 0.71, 95% CI 0.3 to 1.7; UPA 10 mg: OR 0.39, 95% CI 0.1 to 1.1), or Hb levels (MD –0.2, 95% CI –0.6 to 0.2). No clear difference was found in fibroid volume reduction when comparing GnRHA with cabergoline (MD –12.71 mL, 95% CI –5.9 to –31.3). Pretreatment with an SPRM (UPA, MFP, CDB-2914, and
ASP) vs placebo was associated with greater reductions in uterine or fibroid volume than placebo and an increase in preoperative Hb levels (MD +0.93 g/dL; +0.5 to +1.4). UPA and ASP were also associated with greater reductions in bleeding before surgery (UPA 5 mg: OR 41.41, 95% CI 15.3 to 112.4; UPA 10 mg: OR 78.83, 95% CI 24.0 to 258.7; ASP: MD –166.9 mL; 95% CI –277.6 to –56.2).

This analysis led to the conclusion that there is good evidence that preoperative use of a GnRHA reduces uterine and fibroid volume and increases preoperative Hb levels. In the case of hysterectomy, blood loss, operation time, and complication rates were also reduced.

Conclusions
Attempts at a nonsurgical treatment of uterine leiomyomas probably began hundreds of years ago, but scientifically validated modalities became available only some 40 years ago. During this relatively short period of time, several regimens were introduced using different categories of drugs. Today, the most promising belong to two categories: PR modulators and orally active GnRHR blockers.

Disclosure
The authors report no conflicts of interest in this work.

References


Therapeutics and Clinical Risk Management 2019:15

83. Tucci FC, Zhu Y-F, Struthers RS, et al. 3-[(2R)-Amino-2-phenylethyl]-


78. Flierman PA, Oberyé JJ, Hulst VP, de Blok S. Rapid reduction of leio-

77. Britten JL, Malik M, Levy G, Mendoza M, Catherino WH. Gonadotropin-


75. Oberyé JJ, Hulst VP, de Blok S. Rapid reduction of levodopa to dopamine.

74. Layfield JD, Pfaus JG, Blakely RF, et al. An estradiol/norethindrone add-back 

73. Bremner WJ, Elfvin ME, Witoelar E, et al. Randomized controlled trial of 

72. Lee SY, Dugas S, Tucci FC, et al. Discovery and pharmacological character-

71. Zibbell JE, Bensen JT, Nerson JZ, et al. Randomized controlled trial of 

70. Maruo T, Matsuo H, Shimomura Y, et al. Effects of progesterone on 


66. Flierman PA, Oberyé JJ, Hulst VP, de Blok S. Rapid reduction of levodopa to 


63. Pohl O, Marchand L, Fawkes N, Gotteland J-P, Loumaye E. 


60. Miwa K, Hitaka T, Imada T, et al. Discovery of 1-(2,6-difluorobenzyl)-5-


55. Friedman AJ, Barbieri RL, Doubilet PM. A randomized, double-blind 


52. Struthers RS, Chen T, Campbell B, et al. Suppression of serum 


50. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotro-

49. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotro-


46. Kim SM, Yoo T, Lee SY, et al. Effect of SKI2670, a novel, orally active, 


43. Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-

42. Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-

41. Surrey E, Taylor HS, Giudice L, et al. Long-term outcomes of elagolix in 

40. Ng J, Chwaisi K, Carter DC, Klein CE. Dose-dependent suppression of 

39. Archer DF, Stewart EA, Jain RJ, et al. Elagolix for the management of 


37. Zhu Y-F, Gross TD, Guo Z, et al. Identification of 1-aryl-3-(2-


35. Friedman AJ, Barbieri RL, Doubilet PM. A randomized, double-blind 

34. Miwa K, Hitaka T, Imada T, et al. Discovery of 1-(2,6-difluorobenzyl)-5-


25. Wagenfeld A, Saunders PTK, Whitaker L, Critchley HOD. Selective 


7. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotro-


5. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotro-


2. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotro-


For personal use only.

Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 30-Nov-2019


